A. Logan

发表

Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.

V. Carlton, A. Logan, N. Vashi, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission

A. Logan, K. Gaensler, Catherine C. Smith, 2016, Leukemia & lymphoma.

Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice.

I. Weissman, A. Logan, Christopher Y. Park, 2019, Blood.

Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer

H. Wakelee, J. Riess, A. Logan, 2012, Cancer investigation.

The road to purified hematopoietic stem cell transplants is paved with antibodies.

I. Weissman, A. Logan, J. Shizuru, 2012, Current opinion in immunology.

Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting.

A. Logan, L. Goodnough, 2010, Hematology. American Society of Hematology. Education Program.

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

R. Houot, A. Logan, F. Milletti, 2021, The Lancet.

Acute Lymphoblastic Leukemia, Version 2.2021

Patrick W. Burke, A. Logan, M. Liedtke, 2021 .

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.

A. Logan, D. DeAngelo, M. Bishop, 2021, Blood.

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

A. Logan, D. Miklos, M. Flowers, 2017, Blood.

Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.

J. Radich, A. Logan, B. Wood, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer.

A. Logan, M. Majure, 2016, Annals of translational medicine.

Cancer vaccines and T cell therapy.

R. Advani, H. Kohrt, D. Czerwinski, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent

Patricia A. Young, A. Logan, A. Goodman, 2022, British journal of haematology.

Appendix Table 4, Clinical trials on the off-label use of rFVIIa that are registered on an online database

Douglas K Owens, Ingram Olkin, Kathryn M McDonald, 2010 .

Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.

A. Logan, D. Miklos, M. Flowers, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia

A. Melnick, A. Logan, P. Koeffler, 2014, Proceedings of the National Academy of Sciences.

Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice.

I. Weissman, A. Logan, D. Kohn, 2019, Blood.

Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease.

A. Logan, J. Koo, E. Sorenson, 2015, JAMA dermatology.

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

J. Byrd, M. Dyer, A. Logan, 2016, Blood.

Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia

A. Logan, L. Muffly, V. Mittal, 2022, American journal of hematology.

The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters.

A. Logan, S. Chan, 2017, Blood reviews.

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

A. Logan, D. Howard, J. Liesveld, 2021, Blood.

Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019.

A. Logan, K. Gregory, D. DeAngelo, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation.

A. Logan, D. Miklos, K. Alimoghaddam, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications

I. Olkin, K. McDonald, D. Owens, 2011, Annals of Internal Medicine.

Off-Label Use of Recombinant Factor VIIa

R. Stafford, A. Logan, V. Yank, 2011 .

Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation

A. Logan, E. Holler, L. Akard, 2020, Antimicrobial Agents and Chemotherapy.

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

R. Houot, A. Logan, M. Bishop, 2022, Journal of hematology & oncology.

Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care

I. Olkin, K. McDonald, D. Owens, 2010 .

Off-Label Use of Recombinant Factor VIIa in U.S. Hospitals: Analysis of Hospital Records

R. Stafford, A. Logan, V. Yank, 2011, Annals of Internal Medicine.

Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?

A. Logan, B. Schwartz, J. Babik, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Plasma Cell–Free DNA Next-Generation Sequencing to Diagnose and Monitor Infections in Allogeneic Hematopoietic Stem Cell Transplant Patients

A. Logan, David K. Hong, S. Bercovici, 2018, Open forum infectious diseases.

415. Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis

A. Logan, B. Schwartz, J. Babik, 2018, Open Forum Infectious Diseases.

Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

R. Houot, A. Logan, F. Milletti, 2021 .

Integrated Self-Inactivating Lentiviral Vectors Produce Full-Length Genomic Transcripts Competent for Encapsidation and Integration

A. Logan, T. Kafri, D. Haas, 2004, Journal of Virology.

Next-Generation Sequencing Reveals Clonal Evolution at the Immunoglobulin Loci in Chronic Lymphocytic Leukemia

V. Carlton, A. Logan, M. Faham, 2014 .

High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment

James L. Zehnder, Wenzhong Xiao, Ismael Buño, 2011, Proceedings of the National Academy of Sciences.

Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia.

V. Carlton, F. Pépin, A. Logan, 2012, Blood.

The Moloney Murine Leukemia Virus Repressor Binding Site Represses Expression in Murine and Human Hematopoietic Stem Cells

A. Logan, C. Lutzko, D. Haas, 2003, Journal of Virology.

Factors influencing the titer and infectivity of lentiviral vectors.

A. Logan, D. Haas, D. Kohn, 2004, Human gene therapy.

Advances in lentiviral vector design for gene-modification of hematopoietic stem cells.

A. Logan, C. Lutzko, D. Kohn, 2002, Current opinion in biotechnology.

NCCN GUIDELINES ® INSIGHTS CE Acute Lymphoblastic Leukemia , Version 1 . 2019 Featured Updates to the NCCN Guidelines

A. Logan, O. Frankfurt, H. Kantarjian, 2017 .

Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?

A. Logan, 2022, Best practice & research. Clinical haematology.

Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia

B. Narasimhan, V. Carlton, A. Logan, 2013, Leukemia.

4.11 High-Throughput VDJ Sequencing for Chronic Lymphocytic Leukemia: Minimal Residual Disease Quantification and Immunoglobulin Repertoire Assessment Following Hematopoietic Cell Transplantation

A. Fire, W. Xiao, M. Mindrinos, 2011, Clinical Lymphoma Myeloma and Leukemia.

Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options

A. Logan, M. Liedtke, M. Cho, 2012, Hematology.

A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients

Larry R. Smith, A. Logan, P. Chevallier, 2021, EClinicalMedicine.

Acute Liver Failure Secondary to Hemophagocytic Lymphohistiocytosis during Pregnancy

A. Logan, R. Gill, J. Lai, 2016, ACG case reports journal.

Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

A. Logan, M. Liedtke, Deborah A. Freedman-Cass, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond

A. Logan, N. Pemmaraju, N. Majhail, 2021, Current Hematologic Malignancy Reports.

Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation.

Chiung-Yu Huang, A. Logan, C. Andreadis, 2020, Journal of geriatric oncology.

Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency

I. Weissman, A. Logan, K. Weinberg, 2019, Blood.

Toxicity-Free Hematopoietic Stem Cell Engraftment Achieved with Anti-CD117 Monoclonal Antibody Conditioning

I. Weissman, A. Logan, K. Weinberg, 2019, Biology of Blood and Marrow Transplantation.

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

A. Logan, A. Leavitt, Catherine C. Smith, 2019, Blood.

Deep B and T Cell Repertoire Sequencing to Evaluate Minimal Residual Disease and T Cell Responses in a Therapeutic Vaccine Trial for Mantle Cell Lymphoma

R. Advani, H. Kohrt, D. Czerwinski, 2012 .

Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.

B. Liu, B. Hann, A. Logan, 2016, The Journal of clinical investigation.

Sequencing antigen‐targeting antibodies and cellular therapies in adults with relapsed/refractory B‐cell acute lymphoblastic leukemia

A. Logan, E. Jabbour, W. Stock, 2023, American journal of hematology.

Trial in Progress: Tagraxofusp-Based Therapy to Eradicate Measurable Residual Disease of Acute Myelogenous Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

A. Logan, C. Tseng, G. Schiller, 2022, Blood.

Rituximab Provides Steroid-Sparing Therapy in New-Onset Chronic Graft-Versus-Host Disease

A. Logan, D. Miklos, B. Sahaf, 2013 .

Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia.

S. Asthana, M. Carroll, A. Logan, 2019, Cancer discovery.

Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids

A. Logan, D. Miklos, M. Flowers, 2016 .

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

A. Logan, H. Kantarjian, F. Ravandi, 2018, American journal of hematology.

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.

A. Logan, M. Faham, K. Kong, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impaired B Cell Clonotype Diversification After Allogeneic Hematopoietic Cell Transplantation Predicts Graft-Versus-Host Disease

V. Carlton, A. Logan, M. Faham, 2013 .

Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia

A. Logan, L. Muffly, V. Mittal, 2020, Transplantation and Cellular Therapy.

The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.

A. Logan, Catherine C. Smith, Kimberly C. Lin, 2022, Molecular cancer therapeutics.

Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results

A. Logan, P. Munster, C. Andreadis, 2019, Clinical Cancer Research.

SOHO State of the Art Updates and Next Questions: Novel Transplant and Post-Transplant Options in Acute Lymphoblastic Leukemia.

A. Logan, 2022, Clinical lymphoma, myeloma & leukemia.

Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia

A. Logan, J. Saba, 2017, Clinical case reports.

Novel Transplant and Post-Transplant Options in ALL

A. Logan, 2021 .

Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study

W. Wood, A. Logan, A. Goodman, 2021, Blood.

End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

A. Logan, M. Bishop, J. Pagel, 2019, Journal of Clinical Oncology.

Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia.

A. Logan, Hugo Akabane, 2020, Clinical advances in hematology & oncology : H&O.

Patterns and predictors of functional decline after alloHCT in older adults.

Chiung-Yu Huang, A. Logan, K. Gaensler, 2022, Transplantation and cellular therapy.

Anthracyclines in a patient with acute leukemia and severe cardiomyopathy requiring mechanical support: A case report

A. Logan, L. Klein, M. Aras, 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis

A. Logan, Jerry C Lee, Aaron C. Logan, 2023, Cancers.

Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.

Chiung-Yu Huang, A. Logan, K. Gaensler, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.

V. Wang, D. Carbone, A. Logan, 2021, Blood cancer discovery.

Lower leukemia burden maximizes the impact of blinatumomab therapy

A. Logan, 2023, Cancer.

JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID)

I. Weissman, A. Logan, K. Weinberg, 2021, Blood.

Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients

Connie Y. C. Ma, A. Logan, B. Gjertsen, 2021, European journal of haematology.

High Risk of Early Mortality in Adult Patients with Acquired Hemophagocytic Lymphohistiocytosis.

Ash A. Alizadeh, H. Kohrt, A. Logan, 2009 .

Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant

A. Logan, G. Mannis, H. Abdulhaq, 2018, Case reports in hematology.

Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis

T. Naoe, A. Logan, A. Leavitt, 2015, Bone Marrow Transplantation.

A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.

L. Benet, A. Logan, K. Gaensler, 2015, Clinical lymphoma, myeloma & leukemia.

Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.

Chiung-Yu Huang, A. Logan, C. Andreadis, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk Stratification

Corey E. Hayford, A. Olshen, A. Logan, 2023, bioRxiv.

Use of the Quantitative Karius® Plasma Next Generation Sequencing Cell-Free Pathogen DNA Test to Detect and Monitor Cytomegalovirus Infection in Allogeneic Stem-Cell Transplant Recipients

A. Logan, David K. Hong, S. Zompi, 2019, Biology of Blood and Marrow Transplantation.

Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma

H. Kohrt, A. Logan, M. Liedtke, 2008, Leukemia & lymphoma.

Demographics, motivations, and experiences of participants in transplantation or cellular therapy fellowships.

A. Logan, T. Anagnostou, N. Majhail, 2023, Transplantation and Cellular Therapy.

Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia Using High-Throughput Sequencing of Multiple Immunoreceptor Genes Predicts Relapse and Survival After Allogeneic Hematopoietic Cell Transplantation.

T. Willis, V. Carlton, A. Logan, 2012 .

High-Throughput Immunoglobulin Gene Sequencing Quantifies Minimal Residual Disease in CLL with 10e-6 Sensitivity and Strongly Predicts Relapse After Allogeneic Hematopoietic Cell Transplantation

T. Willis, V. Carlton, A. Logan, 2011 .

Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.

J. Radich, A. Logan, C. Hourigan, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.

A. Logan, E. Tholouli, W. Brugger, 2023, Journal of Clinical Oncology.